Table 5.

TCRVβ families identified in antigen-specific TCC of recipient or donor origin or from healthy controls


Patient/control no.

No. of TCCs tested

R/D origin

No. of TCC-TCRVβ families identified
CBT-sib    
2     
3-5 mo after CBT   11   D   7-Vβ2; 4-Vβ21  
3     
3-5 mo after CBT   62   D   28-Vβ2; 9-Vβ12; 13-Vβ13; 12-Vβ24  
12-15 mo after CBT   13   D   2-Vβ1; 3-Vβ6; 2-Vβ8; 6-Vβ13  
4     
3-5 mo after CBT   7   R   4-Vβ8; 3-Vβ13  
5     
3-5 mo after BMT   51   D   42-Vβ2; 9-Vβ8  
12-15 mo after CBT   47   D   37-Vβ2; 10-Vβ3  
9     
3-5 mo after CBT   15   R   12-Vβ13; 3-Vβ2  
12-15 mo after CBT   14   R   10-Vβ13; 4-Vβ6  
CBT-ud    
12     
12-15 mo after CBT   12   D   7-Vβ1; 5-Vβ21  
13     
3-5 mo after CBT   32   D   12-Vβ1; 7-Vβ13; 7-Vβ21; 6-Vβ23  
12-15 mo after CBT   16   D   11-Vβ1; 2-Vβ5; 3-Vβ8  
Control    
17   16   NA   4-Vβ1; 2-Vβ3; 2-Vβ5; 3-Vβ8; 3-V β13; 2-V β19  
18   29   NA   6-Vβ2; 5-Vβ3; 5-Vβ5; 4-Vβ6; 5-V β13; 4-V β19  
19
 
68
 
NA
 
10-Vβ1; 11-Vβ2; 10-Vβ8; 9-Vβ12; 9-Vβ17; 10-Vβ20; 9-Vβ22
 

Patient/control no.

No. of TCCs tested

R/D origin

No. of TCC-TCRVβ families identified
CBT-sib    
2     
3-5 mo after CBT   11   D   7-Vβ2; 4-Vβ21  
3     
3-5 mo after CBT   62   D   28-Vβ2; 9-Vβ12; 13-Vβ13; 12-Vβ24  
12-15 mo after CBT   13   D   2-Vβ1; 3-Vβ6; 2-Vβ8; 6-Vβ13  
4     
3-5 mo after CBT   7   R   4-Vβ8; 3-Vβ13  
5     
3-5 mo after BMT   51   D   42-Vβ2; 9-Vβ8  
12-15 mo after CBT   47   D   37-Vβ2; 10-Vβ3  
9     
3-5 mo after CBT   15   R   12-Vβ13; 3-Vβ2  
12-15 mo after CBT   14   R   10-Vβ13; 4-Vβ6  
CBT-ud    
12     
12-15 mo after CBT   12   D   7-Vβ1; 5-Vβ21  
13     
3-5 mo after CBT   32   D   12-Vβ1; 7-Vβ13; 7-Vβ21; 6-Vβ23  
12-15 mo after CBT   16   D   11-Vβ1; 2-Vβ5; 3-Vβ8  
Control    
17   16   NA   4-Vβ1; 2-Vβ3; 2-Vβ5; 3-Vβ8; 3-V β13; 2-V β19  
18   29   NA   6-Vβ2; 5-Vβ3; 5-Vβ5; 4-Vβ6; 5-V β13; 4-V β19  
19
 
68
 
NA
 
10-Vβ1; 11-Vβ2; 10-Vβ8; 9-Vβ12; 9-Vβ17; 10-Vβ20; 9-Vβ22
 

NA indicates not applicable.

or Create an Account

Close Modal
Close Modal